Loading
Castle Biosciences Inc Stock: price and insider trades · United States
Castle Biosciences Inc: what insiders have been doing
Castle Biosciences Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Castle Biosciences Inc logged 192 filings by 16 insiders.
Only sales appear on the open market, 133 sales in all totalling €13.3M, filed by 4 insiders. The totals exclude 8 filings filed without an amount. One trade stands out by size: a sale of €643k from Stokes Frank, disclosed on 18 August 2026, or 0.067% of market capitalisation.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 192 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 3 purchases and 323 sales. The 10-K for the year ended 31 December 2025 shows 344.2 m USD of revenue and -24.2 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Vivos Inc and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
471
Thresholds
n/a
Buy Volume
€68,143
3 ops. · all time
Sell Volume
€34M
323 ops. · all time
Who traded when
BuySaleDerek J. Maetzold114 sales
Kristen M. Oelschlager18 sales
Tobin W. Juvenal16 sales
Bradbury Daniel9 sales
Stokes Frank7 sales
Since the insiders bought
- +54.5%Entry US$14.91 · Close at T+365 US$23.03
- -22.4%Entry US$25.71 · Close at T+365 US$19.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Castle Biosciences Inc Strong Buy (bullish), based on 9 analysts. Average price target: US$45.22.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,638 of 26,261 companies
40.3
score / 100
Value40
Quality41
FCF yld2.9%
Earn yld-2.5%
EV/EBITDA·
ROE-4.2%
Gross mgn79%
Net mgn-7.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$31.96
Analyst consensus
9 analystsStrong buy
US$35.00Target US$45.22(+41%)US$57.00
Income statement
RevenueUS$344.2M
Gross profitUS$273.2M79% margin
EBITDAUS$11.3M3% margin
Net income-US$24.2M-5.4% margin
Valuation
PER (forward)-35.0x
P/Book2.1x
Beta0.95
Balance sheet & cash
Market capUS$976.4M
Total debtUS$36.9M
Free Cash FlowUS$28.3M
Debt / Equity8%
Profitability & ownership
ROE-4.2%
ROA-1.4%
% insiders2.4%
% institutions90.9%
Last declaration on 14 October 2026
Declarations471 total
3,288 shares@ US$33.640.011% mcap4.0% of flowCommon StockSEC:0001628280-26-065870:0
13,154 shares@ US$32.760.041% mcap19.3% of flowCommonSEC144:0001958244-26-000654
8,165 shares@ US$2.390.0018% mcap0.1% of flowCommon StockSEC:0001628280-26-065327:0
8,580 shares@ US$35.5660.028% mcap1.5% of flowCommon StockSEC:0001628280-26-065327:1
3,198 shares@ US$35.5660.010% mcap0.6% of flowCommon StockSEC:0001628280-26-065327:2
2,718 shares@ US$35.5660.0088% mcap0.5% of flowCommon StockSEC:0001628280-26-065327:3
28,992 shares@ US$36.650.097% mcap20.7% of flowCommonSEC144:0001958244-26-000640
4,153 shares@ US$3.380.0013% mcap0.3% of flowCommon StockSEC:0001628280-26-064912:0
2,807 shares@ US$35.750.0091% mcap2.0% of flowCommon StockSEC:0001628280-26-064912:1
1,346 shares@ US$36.380.0044% mcap1.0% of flowCommon StockSEC:0001628280-26-064912:2
4,153 shares@ US$35.530.013% mcap19.6% of flowCommonSEC144:0001950047-26-009947
5,543 shares@ US$35.4980.018% mcap7.3% of flowCommon StockSEC:0001628280-26-064267:0
1,034 shares@ US$34.200.0032% mcap1.3% of flowCommon StockSEC:0001628280-26-064267:1
8,580 shares@ US$35.3340.027% mcap1.5% of flowCommon StockSEC:0001628280-26-063221:1
3,198 shares@ US$35.3340.010% mcap0.6% of flowCommon StockSEC:0001628280-26-063221:2
2,718 shares@ US$35.3340.0087% mcap0.5% of flowCommon StockSEC:0001628280-26-063221:3
8,580 shares@ US$2.390.0019% mcap0.1% of flowCommon StockSEC:0001628280-26-063221:0
3,306 shares@ US$32.3240.0096% mcap4.2% of flowCommon StockSEC:0001628280-26-062255:0
3,294 shares@ US$35.1420.010% mcap4.6% of flowCommon StockSEC:0001628280-26-062255:1
8,584 shares@ US$2.390.0018% mcap0.1% of flowCommon StockSEC:0001628280-26-062047:0
8,361 shares@ US$32.000.024% mcap1.3% of flowCommon StockSEC:0001628280-26-062047:1
2,656 shares@ US$32.000.0076% mcap0.4% of flowCommon StockSEC:0001628280-26-062047:3
83 shares@ US$32.780.0002% mcap0.0% of flowCommon StockSEC:0001628280-26-062047:5
3,124 shares@ US$32.000.0090% mcap0.5% of flowCommon StockSEC:0001628280-26-062047:2
223 shares@ US$32.780.0007% mcap0.0% of flowCommon StockSEC:0001628280-26-062047:4
25 of 471 declarations
About Castle Biosciences Inc
Castle Biosciences, Inc. (NASDAQ: CSTL) is a U.S.-based molecular diagnostics company headquartered in Friendswood, Texas, in the United States. For French-speaking investors, it is a healthcare specialist focused on prognostic and diagnostic tests designed to improve treatment decisions in areas with meaningful unmet medical need. The company was founded in 2007 by Derek Maetzold, who remains its President and Chief Executive Officer. Its business model is built around proprietary laboratory-developed tests that aim to deliver clinically actionable information derived from tumor biology and related molecular signatures.
Castle’s legacy and still-core franchise is dermatologic oncology. Its portfolio includes DecisionDx-Melanoma, DecisionDx-SCC, and MyPath Melanoma, which are intended to help clinicians refine risk assessment for patients with cutaneous melanoma, cutaneous squamous cell carcinoma, and suspicious pigmented lesions. The company has also expanded beyond skin cancer into gastroenterology through TissueCypher, a test used to identify Barrett’s esophagus patients at higher risk of progression to esophageal cancer. More recently, Castle launched AdvanceAD-Tx to support systemic treatment decision-making in moderate-to-severe atopic dermatitis, underscoring a strategy of broadening its franchise into adjacent high-value disease areas.
Read moreShow less
From a competitive standpoint, Castle positions itself as a focused specialist in high-utility molecular testing, differentiated by clinical evidence and physician adoption rather than scale alone. The company emphasizes a substantial body of peer-reviewed publications and accumulating real-world data that support the clinical validity and utility of its tests versus conventional pathology or staging approaches. Operationally, its footprint remains U.S.-centric, with clinical laboratories in Phoenix and Pittsburgh alongside its new corporate headquarters in Friendswood. That setup supports both commercialization and laboratory execution while keeping the company close to U.S. clinicians and payer dynamics.
Recent developments highlight improving momentum. In the first quarter of 2026, Castle reported revenue of $83.7 million and raised full-year 2026 revenue guidance to $345–355 million, reflecting strong performance from its core growth drivers, DecisionDx-Melanoma and TissueCypher. The company also announced the grand opening of its new headquarters in Friendswood in March 2026, a sign of long-term investment in infrastructure and capacity. For investors, CSTL offers exposure to a NASDAQ-listed U.S. diagnostics platform with specialized growth franchises, but it also carries the usual risks tied to reimbursement, regulatory scrutiny, and the need to continually prove clinical and economic value.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
